
Opinion|Videos|May 21, 2024
Focusing in on Novel Oral Systemic Therapies for Moderate Plaque Psoriasis: Medcast Video
Lauren Miller, MPAS, PA-C, leads an expert discussion surrounding exciting developments in the treatment landscape of plaque psoriasis.
Advertisement
00:00 Introduction
03:15 The role of APP’s in getting patients access to dermatological care.
06:06 Managing patients with suboptimal controlled plaque psoriasis
13:05 Breaking down barriers to access new treatments for plaque psoriasis.
20:23 Deciding between oral and injectable systemic therapies.
24:25 The mechanism of action of TYK-2 inhibitors
28:24 The safety profile of deucravacitinib
33:14 Monitoring your patients with plaque psoriasis
38:50 Outro
Advertisement
Related to this article

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

Suceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome
4
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
5


